Growth hormone treatment improves final height in children with X-linked hypophosphatemia

Growth hormone treatment improves final height in children with X-linked hypophosphatemia

Abstract Background/aim Despite optimal conventional treatment (oral phosphate supplements and active vitamin D analogs), about 40–50% of children with well-controlled X-linked hypophosphatemia (XLH) show linear growth failure, making them less likely to achieve an acceptable final height. Here, we...

Full description

Bibliographic Details
Main Authors: Julia André, Volha V. Zhukouskaya, Anne-Sophie Lambert, Jean-Pierre Salles, Brigitte Mignot, Claire Bardet, Catherine Chaussain, Anya Rothenbuhler, Agnès Linglart
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Orphanet Journal of Rare Diseases
Subjects:
X-linked hypophosphatemia
Rickets
Fibroblast growth factor 23
Recombinant human growth hormone
Final height
Online Access:https://doi.org/10.1186/s13023-022-02590-5

Internet

https://doi.org/10.1186/s13023-022-02590-5

Similar Items